Yu Lu, Li Jun, Xu Sanpeng, Navia Miranda Mariajose, Wang Guoping, Duan Yaqi
Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Department of Pathology, School of Basic Medical Science, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Diagn Pathol. 2016 Oct 12;11(1):98. doi: 10.1186/s13000-016-0551-x.
Xp11.2 translocation/transcription factor E3 (TFE3) rearrangement renal cell carcinoma (RCC) is a rare subtype of RCC with limited clinical and pathological data.
Here we present an unusual high-grade Xp11.2 translocation RCC with a rhabdoid feature and SMARCB1 (INI1) inactivation in a 40-year-old man with end-stage kidney disease. The histological examination of the dissected left renal tumor showed an organoid architecture of the eosinophilic or clear neoplastic cells with necrosis and high mitotic activity. In some areas, non-adhesive tumor cells with eccentric nuclei were observed. Immunohistochemically (IHC), the tumor cells are positive for TFE3 and the renal tubular markers (PAX2 and PAX8), and completely negative for SMARCB1, an oncosuppressor protein. Break-apart florescence in situ hybridization and reverse transcription polymerase chain reaction confirmed TFE3 rearrangement on Xp11.2 and the presence of ASPSCR1-TFE3 fusion gene. DNA sequencing revealed a frameshift mutation in exon 4 of SMARCB1 gene.
It is important to recognize this rare RCC with both TFE3 rearrangement and SMARCB1 inactivation, as the prognosis and therapeutic strategies, particularly targeted therapies for such tumors, might be different.
Xp11.2易位/转录因子E3(TFE3)重排性肾细胞癌(RCC)是RCC的一种罕见亚型,临床和病理数据有限。
在此,我们报告一例罕见的高级别Xp11.2易位性RCC,具有横纹肌样特征且SMARCB1(INI1)失活,患者为一名40岁患有终末期肾病的男性。对切除的左肾肿瘤进行组织学检查,显示嗜酸性或透明肿瘤细胞呈器官样结构,伴有坏死和高有丝分裂活性。在某些区域,观察到具有偏心核的非粘附性肿瘤细胞。免疫组织化学(IHC)检测显示,肿瘤细胞TFE3及肾小管标志物(PAX2和PAX8)呈阳性,而抑癌蛋白SMARCB1呈完全阴性。断裂荧光原位杂交和逆转录聚合酶链反应证实了Xp11.2上的TFE3重排以及ASPSCR1-TFE3融合基因的存在。DNA测序显示SMARCB1基因第4外显子存在移码突变。
认识到这种同时具有TFE3重排和SMARCB1失活的罕见RCC很重要,因为其预后和治疗策略,尤其是针对此类肿瘤的靶向治疗可能会有所不同。